Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Jinhai International Group Holdings Limited ( (HK:2225) ) is now available.
Jinhai Medical Technology Limited has updated its board composition effective 29 January 2026, confirming a structure that includes three executive directors led by Chairman Chen Guobao and CEO Wang Zhenfei, one non-executive director, and three independent non-executive directors. The board has also reaffirmed the membership and leadership of its audit, remuneration and nomination committees, with independent director Yan Jianjun chairing the audit and remuneration committees and Chairman Chen heading the nomination committee, underscoring the company’s emphasis on independent oversight and corporate governance in line with Hong Kong listing expectations.
The most recent analyst rating on (HK:2225) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on Jinhai International Group Holdings Limited stock, see the HK:2225 Stock Forecast page.
More about Jinhai International Group Holdings Limited
Jinhai Medical Technology Limited, listed in Hong Kong under stock code 2225 and incorporated in the Cayman Islands, operates in the medical technology sector. The company is overseen by a board comprising executive, non-executive and independent non-executive directors, reflecting a standard governance structure for a listed medical-tech enterprise focused on regulatory compliance and stakeholder oversight.
Average Trading Volume: 8,877,408
Technical Sentiment Signal: Buy
Current Market Cap: HK$9.95B
Find detailed analytics on 2225 stock on TipRanks’ Stock Analysis page.